Author

Takayuki Shimose

Observed names: Shimose, T., Shimose, Takayuki, T. Shimose

OpenAlex ID: A5050291988

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

2016 · E. Iwama, K. Sakai, et al. · Annals of Oncology · 92

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

2017 · Eiji Iwama, Yasushi Goto, et al. · Journal of Thoracic Oncology · 52

Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)

2019 · Shun Sasaki, Eiji Oki, et al. · International Journal of Clinical Oncology · 45

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

2018 · Eiji Iwama, Kazuko Sakai, et al. · Cancer Science · 41

PDF

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)

2019 · Koji Nagafuji, Itaru Matsumura, et al. · International Journal of Hematology · 32

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

2019 · Eiji Iwama, Kazuko Sakai, et al. · Cancer · 28

Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes

2016 · Hidetoshi Nitta, Takayuki Shimose, et al. · Medical Oncology · 23

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101)

2020 · Kaname Nosaki, Takeharu Yamanaka, et al. · The Oncologist · 22

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

2019 · Eiji Iwama, Yasushi Goto, et al. · The Oncologist · 15

PDF

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study

2022 · Yusuke Chihara, Takayuki Takeda, et al. · The Oncologist · 13

Current state of yusho and prospects for therapeutic strategies

2017 · Chikage Mitoma, Hiroshi Uchi, et al. · Environmental Science and Pollution Research · 13

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy

2024 · Hayato Kawachi, Tadaaki Yamada, et al. · OncoImmunology · 12

Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study

2017 · Etsuro Nanishi, Hisanori Nishio, et al. · Journal of the American Heart Association · 10

A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)

2017 · Koji Ando, Yasunori Emi, et al. · International Journal of Clinical Oncology · 9

Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)

2018 · Hiroaki Tanioka, Yuji Miyamoto, et al. · Oncology · 8

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial)

2018 · Jun Ishikawa, Itaru Matsumura, et al. · International Journal of Hematology · 7

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED)

2025 · Y. Shiraishi, T. Shimose, et al. · ESMO Open · 6

PDF

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases

2022 · Yoshimasa Shiraishi, Takayuki Shimose, et al. · Cancer Management and Research · 6

PDF

Effects of pericapsular soft tissue and realignment exercises for patients with osteoarthritis of the hip and Harris Hip Score below 60 points

2022 · Kazuo Hayashi, Toshiharu Tsunoda, et al. · Current Medical Research and Opinion · 5

PDF

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)

2025 · Yoshimasa Shiraishi, Takayuki Shimose, et al. · European Journal of Cancer · 4

PDF

Phase II study of durvalumab ( MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study ( LOGIK 2003)

2022 · Hidenobu Ishii, Koichi Azuma, et al. · Thoracic Cancer · 4

PDF

A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.

2017 · Katsunori Shinozaki, Satoshi Yuki, et al. · Journal of Clinical Oncology · 3

290 | Real‐world Safety and Efficacy of Pola‐r‐chp in Patients With Previously Untreated Dlbcl: Analysis of 500 Patients in the Polastar Study

2025 · N. Nakamura, S. Rai, et al. · Hematological Oncology · 2

PDF

A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis

2024 · Hirohiko Shibayama, Atsushi Satake, et al. · Blood · 2

A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non‐small cell lung cancer ( LOGIK1902 )

2024 · Taishi Harada, Tomonari Sasaki, et al. · Thoracic Cancer · 2

PDF

Works count: 46

Citation count: 466

H-index: 12

I10-index: 13